Logo
PLLACELL 1x100mg Vial

PLLACELL 1x100mg Vial

PLLACELL

Aesthetic / cosmetic injectable
  • Manufactured in South Korea by BS Pharm Korea Co., Ltd., an exporter with verified certificates listed on TradeKorea.
  • Marketed internationally as a collagen Boosting skin booster under beauty / aesthetic product categories.
  • Publicly available information does not clearly document a specific UK MHRA medicinal product licence for PLLACELL; users should verify local regulatory status before use.
  • Some distributors reference general quality assurance and certification, but explicit, product Specific CE or FDA device approvals are not clearly detailed in accessible sources.
PLLA-based skin booster (poly-L-lactic acid collagen stimulator)

Description

PLLACELL 1x100mg Vial is a next-generation Korean poly-L-lactic acid (PLLA) skin booster and collagen stimulator. Each vial contains a total of 100 mg of actives, combining 35 mg poly-L-lactic acid, 8 mg polynucleotides (PN, sodium DNA), glutathione, vitamin C and sodium hyaluronate in a lyophilised, light-pink, ball-shaped powder. Once reconstituted with sterile water and injected by trained professionals, it biostimulates collagen, restores facial volume, improves elasticity, deeply hydrates and brightens the skin. PLLACELL is designed for professional aesthetic use on the face, neck, décolletage and hands to address fine lines, dullness, uneven texture and early to moderate signs of ageing.

Bnefits

  • Stimulates natural collagen production for gradual volume restoration and skin tightening
  • Improves skin elasticity and firmness by supporting dermal matrix regeneration
  • Deeply hydrates the skin via sodium hyaluronate, enhancing softness and suppleness
  • Brightens and evens skin tone with antioxidant glutathione and vitamin C
  • Reduces the appearance of fine lines, wrinkles and some post-acne or textural irregularities
  • Supports skin repair and healing through polynucleotide-mediated tissue regeneration
  • Provides long-lasting rejuvenation, with effects that can persist many months after a treatment course
  • Multi-area use (face, neck, décolletage, hands) for non-surgical, full-face skin quality improvement
  • Designed for gradual, natural-looking results without abrupt volumetric change
  • Professional-use-only formulation with protocols and e-book materials available for clinicians

Indications

  • Non-surgical skin rejuvenation and biostimulation in adult patients
  • Fine lines and superficial to moderate wrinkles
  • Loss of skin elasticity and early skin laxity
  • Dull, devitalised or photo-damaged skin
  • Uneven texture and mild post-acne or atrophic scarring appearance (as part of a broader regimen)
  • Mild to moderate volume loss where a collagen-stimulating booster is appropriate
  • Dehydrated skin with compromised barrier function
  • Skin tone irregularity and mild hyperpigmentation where antioxidant support is desired
  • Treatment areas typically include face, neck, décolletage and hands (for professional use only)

Composition

  • Poly-L-lactic acid (PLLA) 35 mg – primary collagen-stimulating polymer for volume and wrinkle reduction
  • Polynucleotides (PN, Sodium DNA) 8 mg – supports tissue repair, regeneration and dermal cell turnover
  • Sodium hyaluronate – provides deep hydration and supports barrier and tissue regeneration (amount not specified)
  • Glutathione – antioxidant that helps reduce oxidative stress and supports skin brightening (amount not specified)
  • Vitamin C (ascorbic acid) – antioxidant and collagen co-factor that supports radiance and even tone (amount not specified)
  • Excipients and stabilisers suitable for lyophilised injectable cosmetic/medical-use formulations (not fully specified in public sources)

Formulation

  • Lyophilised, light pink, ball-shaped powder in a glass vial
  • Total active concentration: 100 mg per vial (including 35 mg PLLA and 8 mg polynucleotides)
  • Intended to be reconstituted with approximately 6 mL (6 cc) of sterile distilled water for injection before use
  • Once reconstituted, designed for intradermal / superficial to mid-dermal administration by trained professionals using techniques such as mesotherapy-style microinjections, microneedling devices, dermarollers or multi-needle injectors, following the manufacturer’s protocol

Packaging

  • 1 x 100 mg lyophilised powder vial per box
  • Sterile, single-patient vial for single-use reconstitution and administration
  • Outer carton labelled with product name, batch number, expiry date and manufacturer details (as per regional packaging)
  • Professional-only packaging intended for clinic and aesthetic practice distribution

Usage

  • For professional use only; must be administered by trained and appropriately qualified healthcare or aesthetic practitioners in accordance with local regulations.
  • Reconstitute the 100 mg lyophilised PLLACELL vial with approximately 6 mL of sterile distilled water for injection, following the manufacturer’s protocol and aseptic technique.
  • Allow sufficient time for the lyophilised micro-spheres and matrix to fully hydrate and disperse, ensuring a homogeneous suspension before administration (gently swirling rather than vigorous shaking, as per local protocol).
  • Administer the reconstituted product to the superficial to mid-dermis using appropriate techniques such as mesotherapy-style microinjections, microneedling-assisted delivery, dermaroller or multi-needle injectors, or other methods outlined in the official PLLACELL protocol e-book.
  • Treatment areas typically include face, neck, décolletage and hands, with specific patterns, volumes per point and depth of injection determined by the practitioner based on patient assessment and manufacturer guidance.
  • A typical treatment course described by clinics and distributor guidance consists of around 3–4 sessions spaced approximately 3–4 weeks apart; some advanced protocols suggest up to 4–6 sessions at 2-week intervals depending on skin condition and goals.
  • Patients should be counselled on expected transient reactions (redness, swelling, bruising), aftercare measures (avoiding makeup, alcohol, intense exercise and direct sun exposure for a short period) and the gradual nature of PLLA-mediated collagen stimulation.
  • Practitioners should consult the official PLLACELL brochure and e-book protocols from the manufacturer/distributor for detailed reconstitution instructions, contraindications, precautions and technique recommendations.

Contraindications

  • Known hypersensitivity or allergy to any component of the formulation (poly-L-lactic acid, polynucleotides, sodium hyaluronate, vitamin C, glutathione or excipients).
  • Active skin infection, inflammation or dermatitis at the proposed treatment area (e.g. herpes simplex, bacterial or fungal infections).
  • History of severe allergic reactions or anaphylaxis to injectable fillers or mesotherapy-style products.
  • Pregnancy or breastfeeding (commonly listed as a precaution/contraindication by aesthetic clinics).
  • Known tendency to keloid formation or hypertrophic scarring in the treatment area.
  • Uncontrolled autoimmune diseases or significant systemic illnesses where injectable biostimulators may be unsuitable, as determined by a qualified clinician.
  • Concurrent use of therapies, medications or systemic conditions that may significantly impair wound healing, increase bleeding risk or alter immune response, unless a medical prescriber has assessed and approved treatment.
  • Any contraindications outlined in the official PLLACELL manufacturer documentation or by local regulatory guidance for PLLA-based biostimulators.

Adverse Effects

  • Expected, usually transient injection-related reactions such as erythema (redness), swelling, tenderness, itching, warmth, minor pain or bruising at the injection sites.
  • Temporary pinprick marks or mild oedema following mesotherapy-style, microneedling or multi-needle injection techniques.
  • Occasional small palpable product deposits, papules or nodules in the treated area, which generally settle as the product integrates and collagen is remodelled; persistent nodules require clinical assessment.
  • Rare risk of more significant inflammatory reactions, granuloma formation or foreign-body response, as with other PLLA-based biostimulators.
  • Very rare but serious injection-related complications (e.g. vascular occlusion, tissue necrosis, infection) if product is inadvertently placed intravascularly or if asepsis is not maintained; these require urgent specialist management.
  • Any other adverse effects consistent with injectable aesthetic procedures, which must be assessed and managed by appropriately qualified healthcare professionals.

Storage Conditions

  • Store unopened vials at room temperature, typically between 2°C and 25°C, as specified by the manufacturer.
  • Keep in a dry place away from direct sunlight and excessive heat or humidity.
  • Do not freeze the product.
  • Store in the original packaging until use to protect from light and contamination.
  • Use reconstituted product within the timeframe recommended by the manufacturer and do not reuse leftover solution from a previously opened vial.

Duration

Commonly described treatment plans involve 3\u20134 sessions spaced 3\u20134 weeks apart (with some protocols extending to 4\u20136 sessions every 2 weeks), followed by maintenance as clinically indicated. Clinical and manufacturer information suggest that collagen-stimulating effects and visible improvements can persist for many months and in some cases up to approximately 18\u201324 months after a completed course, depending on individual factors and adjunctive skincare.

Onset

Hydration and radiance may be noticeable within days to a couple of weeks after the first session, while collagen-stimulating effects from PLLA and polynucleotides typically build gradually over approximately 4\u20136 weeks and continue to evolve over several months with repeated treatments.

Browse more Aesthetic / cosmetic injectable

Top Treatments

Top Cities in the UK